Company Overview and News


Add OPT
to your dashboard

Headline News

Opthea Presents Additional Positive Data from OPT-302 Phase 1/2a Wet AMD Trial at ASRS Meeting

2017-08-15 marketwired
MELBOURNE, AUSTRALIA--(Marketwired - Aug 15, 2017) - Opthea Limited (ASX: OPT), a developer of novel biologic therapies for the treatment of eye diseases, today announced further positive results from its Phase 1/2a clinical trial of OPT-302, a novel VEGF-C/D 'Trap' therapy for wet age-related macular degeneration (wet AMD). 

Opthea to Present at the American Society of Retinal Specialists Annual Meeting and the Ophthalmology Innovation Summit

2017-08-09 marketwired
MELBOURNE, AUSTRALIA--(Marketwired - Aug 9, 2017) - Opthea Limited (ASX: OPT), a developer of novel biologic therapies for the treatment of eye diseases, announced today that the Company will present data from its Phase 1/2A clinical trial for its lead program OPT-302 in wet AMD at the 35th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) to be held August 11 -15, 2017.

Opthea to Present at the Wedbush PacGrow Healthcare Conference

2017-08-07 marketwired
MELBOURNE, AUSTRALIA--(Marketwired - Aug 7, 2017) - Opthea Limited (ASX: OPT), a developer of novel biologic therapies for the treatment of eye diseases, today announced that the Company will be presenting at the 2017 Wedbush PacGrow Healthcare Conference taking place on August 15 - 16, 2017 at the Le Parker Meridien in New York, NY. Dr Megan Baldwin, Opthea's Chief Executive Officer will present at 8:00AM Eastern Time on Tuesday, August 15th 2017.

Opthea Receives Notice of Allowance for Key Patent Covering OPT-302 in the United States

2017-07-06 marketwired
Opthea Limited (ASX: OPT), a developer of novel biologic therapies for the treatment of eye diseases, is pleased to announce that it has received a Notice of Allowance from the United States Patent and Trade Mark Office (USPTO) for the Company's Patent Application No. 14/768,701 for its OPT-302 soluble VEGFR-3 (sVEGFR-3) 'trap' molecule. Opthea anticipates the patent will be granted in the second half of 2017.

Opthea Ltd secures notice of allowance for key U.S. patent

2017-07-06 proactiveinvestors.com.au
Opthea Ltd (ASX:OPT) has received a Notice of Allowance from the U.S. patent office for its OPT-302 soluble VEGFR-3 ‘trap’ molecule.

Opthea Completes A$45 Million Capital Raising

2017-04-28 marketwired
MELBOURNE, AUSTRALIA--(Marketwired - Apr 28, 2017) - Opthea Limited (ASX: OPT) ("Opthea"), a developer of novel biologic therapies for the treatment of eye diseases, announced today the completion of its A$45 million capital raising launched on 3 April 2017. The proceeds from this offering enable the acceleration and diversification of the Company's clinical development strategy for OPT-302, its novel VEGF-C/D 'Trap' therapy for wet age-related macular degeneration ("wet AMD") and diabetic macular edema ("DME").

Opthea raises $45M to advance novel therapy for eye diseases

2017-04-28 proactiveinvestors.com.au
Opthea (ASX:OPT) has completed a $45 million capital raising after receiving strong demand from international and domestic healthcare dedicated investment funds.

Opthea reveals positive trial results; launches $45M equity raising

2017-04-03 proactiveinvestors.com.au
Opthea (ASX:OPT) has received positive results from its Phase 1/2A clinical trial of OPT-302, a novel therapy for wet age-related macular degeneration (wet AMD).

Opthea Reports Positive Phase 1/2A Clinical Results for OPT-302 in wet AMD

2017-04-03 marketwired
Company to Host Conference Call Today at 10:30AM Australian Eastern Standard Time/8:30PM EDT (Sunday, April 2nd US)

Opthea Conference Call/Webcast -- Update on OPT-302 Phase 1/2A Wet AMD Clinical Trial

2017-03-31 marketwired
MELBOURNE, AUSTRALIA--(Marketwired - Mar 31, 2017) - Opthea Limited (ASX : OPT), Opthea Limited, a developer of novel biologic therapies for the treatment of eye diseases, will host a conference call and webcast at 10:30am Australian Eastern Standard Time on Monday 3 April (8:30pm US EST on Sunday, April 2).

Opthea receives positive feedback for macular degeneration therapy

2017-03-20 proactiveinvestors.com.au
Opthea (ASX:OPT) has received positive feedback from European regulatory agencies for the clinical development of OPT-302 for the treatment of wet age-related macular degeneration (wet AMD).

Opthea Receives Positive Feedback from European Regulatory Agencies for the OPT-302 Clinical Program in wet AMD

2017-03-20 marketwired
MELBOURNE, AUSTRALIA--(Marketwired - Mar 20, 2017) - Opthea Limited (ASX: OPT), a developer of novel biologic therapies for the treatment of eye diseases, has concluded positive European scientific advice meetings with the United Kingdom's (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) and Sweden's Medical Products Agency (MPA) for the clinical development program of OPT-302, Opthea's novel VEGF-C/D 'Trap' therapy for the treatment of wet age-related macular degeneration (wet AMD).

Opthea Completes FDA Meeting to Inform OPT-302 wet AMD Clinical Program

2017-03-08 marketwired
MELBOURNE, AUSTRALIA--(Marketwired - Mar 8, 2017) - Opthea Limited (ASX: OPT) -- Opthea Limited, a developer of novel biologic therapies for the treatment of eye diseases, has completed a Type C meeting with the U.S. Food and Drug Administration (FDA). The purpose of the meeting was to obtain regulatory guidance on the clinical development program and proposed Phase 2B clinical trial of OPT-302, Opthea's novel VEGF-C/D 'Trap' therapy for the treatment of wet age-related macular degeneration (wet AMD).

Opthea Ltd reports positive results for Phase 1 macular degeneration study

2016-07-26 proactiveinvestors.com.au
Opthea Ltd (ASX:OPT) has reported positive results from a Phase 1 dose escalation study for 20 participants with  the OPT-302 molecule with the standard of care Lucentis® for 20 participants. This first-in-human clinical trial of OPT-302 therapy for wet age-related macular degeneration met safety and tolerability and hence its primary objective as a monotherapy and in combination with standard of care.